Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931110 · ClinicalTrials.gov registry record · Phase 1
Study of IV CBL0137 in Previously Treated Hematological Subjects
A Phase 1 study, sponsored by Incuron.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02931110 is a Phase 1 study that was terminated before completion, run by Incuron. The registered enrollment target is 5 participants.
The verdict
NCT02931110, a Phase 1 study, was terminated before completion, sponsored by Incuron.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV) administered CBL0137 in participants with previously treated hematological malignancies.
Interventions
- DRUG CBL0137
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02931110
The ClinicalTrials.gov registry entry for NCT02931110 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incuron, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBL0137 is the first listed.
NCT02931110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02931110 about?
NCT02931110 is a clinical study titled "Study of IV CBL0137 in Previously Treated Hematological Subjects". This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV) administered CBL0137 in participants with previously treated hematologi...
What is the current status of trial NCT02931110?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-01. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02931110?
The interventions under investigation include: CBL0137 (DRUG).
Who is sponsoring clinical trial NCT02931110?
This trial is sponsored by Incuron, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.